MFN2 and metabolic dysfunction-associated steatohepatitis: Hernandez-Alvarez, M.I. et al. found that the expression of Mfn2 significantly decreased in MAFLD patients, and in the MASH mouse model, upregulating Mfn2 alleviated the MASH phenotype [62].